Skip to main content
. Author manuscript; available in PMC: 2013 Sep 23.
Published in final edited form as: Transplantation. 2006 Dec 15;82(11):1510–1517. doi: 10.1097/01.tp.0000243168.53126.d2

Figure 4.

Figure 4

In vivo proliferation of alloreactive CD8+ T cells. CFSE-labeled CD4−/− C57BL/6 lymphocytes were injected into the lateral vein of irradiated BALB/c recipient mice. Representative histograms of proliferative responses of allogeneic CD8+ T cells from the host spleen (A) and the host lymph nodes (B) are shown. Mice were left untreated or treated with CTLA4/Fc (0.2 mg) or IL-15 mutant/Fcγ2a (1.5 μg) for three days. The mean frequency of proliferative allogeneic CD8+ T cells (RF) from the host spleen (A) are 24.5±6 for untreated mice, 25.75±4.5 for CTLA4/Fc treated mice, and 14.5 ±3 for IL-15 mutant/Fcγ2a treated mice. The mean frequency of proliferative allogeneic CD8+ T cells (RF) the host lymph nodes (B) are 25.5±4 for untreated mice, 20±5 for CTLA4/Fc treated mice and 10±2.5 for IL-15 mutant/Fcγ2a treated mice. Data is represented as the frequency of allogeneic CD8 + T cells (RF) responding to allogens by proliferation. Data is representative of three identical and independent experiments.